Urine N -Acetylaspartate Distinguishes Phenotypes in Canavan Disease
Human Gene Therapy · 2025
DOI: 10.1089/hum.2024.168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2025. Verfasst von Amanda Nagy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Canavan Disease, Aspartic Acid, Amidohydrolases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Canavan disease (CD) is an ultra-rare autosomal recessive leukodystrophy caused by loss-of-function mutations in ASPA, which encodes aspartoacylase (ASPA), leading to accumulation of N -acetylaspartate (NAA). Patients with CD typically present with profound psychomotor deficits within the first 6 months of life and meet few motor milestones. Within CD a subset of patients exhibits a milder phenotype with more milestone acquisition, possibly related to greater residual ASPA activity. An ongoing CD natural history study and a literature search were leveraged to compare urine NAA levels and associated genotypes in patients classified with mild or typical CD, with the hypothesis that urine NAA levels reflect ASPA activity and therefore can distinguish between the two phenotypes. Urine NAA levels were lower, on average ( p < 0.0001), in individuals with mild (mean 525.3, range 25.2–1,335 mmol/mol creatinine [Cr]) compared with typical CD (mean 1,369, range 391.7–2,420 mmol/mol Cr). Mutations R71H and Y288C, variants that may harbor residual ASPA activity, were unique to the mild phenotype population (56%, 14/25) and not found in individuals with a typical phenotype (0%, 0/39). In aggregate, urine NAA levels can distinguish between mild and typical CD phenotypes, suggesting the ability to reflect ASPA activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- University Medical Center Hamburg-Eppendorf, Leukodystrophy Clinic at University Children's Hospital, Hamburg, Germany.
- Department of Neurology, University of California San Francisco, San Francisco, California, USA.
- School of Health and Rehabilitation Sciences, MGH Institute of Health Professions, Boston, Massachusetts, USA.
- BridgeBio Gene Therapy, Palo Alto, California, USA.
ORCID-Profile: Rachel Williams
Förderung
- NINDS NIH HHS
Zitieren
APA
Nagy, A., Eichler, F., Bley, A., Bredow, J., Fay, A., Townsend, E. L., Leiro, B., Shaywitz, A., Laforet, G., Crippen-Harmon, D., & Williams, R. (2025). Urine N -Acetylaspartate Distinguishes Phenotypes in Canavan Disease. Human Gene Therapy. https://doi.org/10.1089/hum.2024.168
Vancouver
Nagy A, Eichler F, Bley A, Bredow J, Fay A, Townsend EL, et al. Urine N -Acetylaspartate Distinguishes Phenotypes in Canavan Disease. Human Gene Therapy. 2025. doi:10.1089/hum.2024.168
BibTeX
@article{Nagy2025,
author = {Nagy, Amanda and Eichler, Florian and Bley, Annette and Bredow, Janna and Fay, Alexander and Townsend, Elise L and Leiro, Beth and Shaywitz, Adam and Laforet, Genevieve and Crippen-Harmon, Danielle and Williams, Rachel},
title = {Urine N -Acetylaspartate Distinguishes Phenotypes in Canavan Disease},
journal = {Human Gene Therapy},
year = {2025},
doi = {10.1089/hum.2024.168}
}
EUVIMED